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To investigate the possibility that we have been under-
estimating the true incidence of acute rejection, we 
began to perform protocol biopsies after kidney trans-
plantation. This analysis looks at the one-week biop-
sies. Between March 1 and October 1, 1999, 100 adult 
patients undergoing cadaveric kidney or kidney/pan-
creas transplantation, or living donor kidney transplan-
tation, underwent 277 biopsies. We focused on the 
subset of biopsies in patients without delayed graft 
function (DGF) and with stable or improving renal func-
tion, who underwent a biopsy 8.2 ± 2.6 d (range 3-
18 d) after transplantation (n = 28). Six (21 %) patients 
with no DGF and with stable or improving renal func-
tion had borderline histopathology, and 7 (25%) had 
acute tubulitis on the one-week biopsy. Of the 277 kid-
ney biopsies, there was one (0.4%) serious hemor-
rhagic complication, in a patient receiving low molecu-
lar weight heparin; she ultimately recovered and has 
normal renal function. Her biopsy showed Banff 1 B tu-
bulitis. In patients with stable or improving renal allo-
graft function early after transplantation, subclinical 
tubulitis may be present in a SUbstantial number of pa-
tients. This suggests that the true incidence of rejec-
tion may be higher than is clinically appreciated. 
Key words: High incidence, protocol biopsies, subclin-
ical acute tubulitis 
Received 20 September 2000, revised and accepted 
for publication 4 January 2001 
Introduction 
Acute rejection after renal transplantation may be associated 
with a variable clinical presentation, The symptoms of fever, 
swelling and pain over the allograft, routinely seen in the aza-
thioprine era (1-3), are extremely unusual today, A rise in 
the serum creatinine, without other obvious cause, ac-
companied by a renal allograft biopsy demonstrating the ap-
propriate histopathologic picture, is the most common pres-
entation (4), However, Rush and his colleagues (5-7), and 
others (8-11), have demonstrated the presence of subclin-
ical acute tubulitis, i,e, histopathologic evidence of acute tu-
bulitis in the presence of stable renal function, We have noted 
similar findings in a small number of simultaneous kidneyl 
pancreas (SPK) recipients who underwent renal allograft bi-
opsy, despite having stable and normal renal function, be-
cause of a rising serum lipase level (i,e, suspected pancreatic 
rejection) (12), This demonstration of unsuspected tubulitis 
raised a concem that we have been systematically underesti-
mating the incidence of acute rejection in our patients. Ac-
cordingly, we began to perform protocol biopsies at one 
week, one month, and one year after transplantation in all of 
our adult patients undergoing renal transplantation, This re-
port describes our initial experience with one-week biopsies. 
Patients and Methods 
Between March 1, 1999 and October 1. 1999, 100 adult pa-
tients undergoing cadaveric kidney or SPK transplantation, or 
living donor kidney transplantation, underwent 277 percu-
taneous renal allograft biopsies. For the purposes of this 
analysis, we focused on a subset of 28 patients who did 
not experience delayed graft function (DGF) (i.e. no ,dialysis 
required after transplantation), and who had stable or improv-
ing renal function, who underwent biopsies at approximately 
one week after transplantation. The other patients either had 
DGF (n = 14) or clinical signs (i.e. a rising serum creatinine) 
that warranted a biopsy (n = 46); they would have under-
gone a biopsy as a matter of course (nine patients did not 
have a one-week biopsy, and three biopsy specimens were 
nondiagnostic). The group of 28 patients were the subset of 
patients who ordinarily would have had no indication to un-
dergo a biopsy, because their allografts were functioning well 
and their serum creatinine levels were either falling or were 
normal and stable, The mean recIpient age was 
48.3±12.1yr (range 22.6-71Ayr; Table 1). Twenty-four 
(86%) patients had undergone cadaveric kidney transplan-
tation, two (7%) SPK transplantation, and two (7%) living-
related donor kidney transplantation. Nineteen (68%) were 
receiving their first kidney transplant. while six (21 %) and 
three (11 %) were undergoing their second and third kidney 
transplantations, respectively The peak/most recent panel re-
active antibody levels (PRA) were 22.1:!: 28.9% and 
1O,5:!: 19,1 %, Biopsies were performed percutaneously 
under real-time ultrasonographic guidance, a mean of 
8.2:!: 2,6 d (3-18) after transplantation. 
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Table 1: Patient demographics 
n=28 
Mean recipient age (yr) 
Mean date of biopsy (postoperative day) 
Cadaveric kidney only 
Simultaneous pancreas/kidney 
Living donor kidney 
1 st transplant 
2nd transplant 
3rd transplant 
Panel reactive antibody (%) 
Peak 
Recent 
Additional baseline immunosuppression 
Mycophenolate mofetil 
Daclizumab 
OKT3 
Azathioprine 
Nothing 
Table 2: Incidence/severity of tubulitis 
No tubulitis 
Borderline 
Banff 1A 
Banff 1 B 
Banff 2A 
48.3:!: 12.1 
8.2:!: 2.6 (range 3-18) 
24 (86%) 
2 (7%) 
2 (7%) 
19 (68%) 
6 (21%) 
3 (11%) 
22.1 :!:28.9 
10.5:!:: 19.1 
18 (64%) 
4 (14%) 
1 (4%) 
1 (4%) 
4 (14%) 
15 (54%) 
6 (21%) 
2 (7%) 
4 (14%) 
1 (4%) 
Immunosuppression was with tacrolimus and steroids. as pre-
viously described (13-15). Eighteen (64%) patients also re-
ceived mycophenolate mofetil 2g/d (15). Four (14%) patients 
received antibody induction with daclizumab 2 mg/kg. at the 
time of transplantation (followed later by 1 mg/kg at 2 and 
4weeks). One (4%) patient received OKT3 induction. one 
(4%) received azathioprine. and four (14%) received no ad-
ditional agent. 
Pathologic evaluation of the biopsies. according to the Banff 
criteria (16). was performed by our transplant pathologists. 
who were blinded regarding the clinical status of the patients. 
Informed consent was obtained prior to each biopsy. 
Results 
Six (21 %) patients without DG F and with stable or improving 
renal allograft function had evidence of borderline histopath-
ology. and seven (25%) had evidence of frank acute tubulitis 
on the one-week biopsy (Table 2). The histopathologic sever-
ity ranged from Banff 1A to Banff 2A (16). Fifteen (54%) pa-
tients had no evidence of acute tubulitis. 
The serial serum creatinine and tacrolimus levels in the two 
groups are shown in Table 3. The mean tacrolimus level on 
the day of the biopsy in the patients with subclinical border-
line or acute tubulitis was significantly lower (16.6::!:: 4.9 ng! 
mL) than in the patients with no evidence of acute rejection 
(25.1 ::!:: 7.6ng/mL: p <0.002). 
There was a significantly higher degree of HLA-DR mis-
matching in the group with subclinical borderline or acute 
tubulitis. There were three (23%) 0 DR mismatches. six 
(46%) 1 DR mismatches. and four (31 %) 2 DR mismatches 
in the group with borderline or acute tubulitis (mean DR mis-
match 1.1 ::!:: 0.8). In the group with no tubulitis. 11 (73%) 
were 0 DR mismatches. and four (27%) were 1 DR mis-
matches (mean DR mismatch 0.3 ::!::0.5:_p <0.05 by the 
Likelihood Ratio test). 
All patients with histologic evidence of subclinical borderline 
or acute tubulitis were treated. In general. patients with bor-
derline changes received a single bolus of steroids. along 
with augmentation of their tacrolimus dosage. Patients with 
Banff 1 A tubulitis or worse received a bolus and a short ster-
oid recycle. in addition to augmentation of their tacrolimus 
dosage. 
Of the 277 biopsies performed. there was one (0.4%) serious 
hemorrhagic complication. in a 40-year-old white female 
with normal and stable renal function. who was receiving low 
Table3: Serial renal function and tacrolimus levels prior to. on the day of. and 7 days following protocol biopsies performed 1 week after 
transplantation 
Borderline or 
acute tubulitis 
(n= 13) 
No tubulitis 
(n = 15) 
'p <0.002. 
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Serum 
creatinine 
(mg/dL) 
Tacrolimus 
levels 
(ng/mL) 
Serum 
creatinine 
(mg/dL) 
Tacrolimus 
levels (ng/mL) 
0-7 
6.0:!::3.1 
20.0:!::4.8 
8.8:!::4.3 
28.4:!:: 12.0 
0-3 0-1 00 0+7 
2.9:!::2.5 2.4:!::2.0 2.1 :!:: 1.7 1.6:!::O.7 
22.0:!:: 6.1 19.1 :!::3.6 16.6 :!::4.9* 20.2:!::4.2 
4.1 :!:3.4 2.7:!:: 1.8 2.3:!:: 1.4 2.1 :!:: 1.5 
24.7:!:: 14.7 22.9:!: 6.4 25.1 :!::7.6 20.8:!:: 6.0 
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molecular weight heparin because of a history of a left ven-
tricular mural thrombus following prevIous coronary artery 
bypass grafting. This patient had been taking coumadin pre-
transplantation; low molecular weight heparin had been dis-
continued for 24h Prior to her biopsy, which was in fact per-
formed uneventfully. She presented 6 h later with pain and 
swelling over the allograft, underwent surgical re-exploration 
with evacuation of a large hematoma, and required multiple 
blood transfusions. She ultimately recovered and has normal 
renal function. Her biopsy showed Banff 1 B tubulitis, for 
which she received a bolus and a recycle of steroids, and 
additional tacrolimus. 
One (4%) of the 28 patients in this group died 2.8months 
after kidney transplantation, of a probable myocardial infarc-
tion. This patient had also developed post-transplant diabetes 
mellitus. The remaining patients are alive with functioning 
allografts. 
The focus of this analysis was placed deliberately on those 
patients who would not ordinarily have undergone a biopsy, 
i.e. those who were doing well. Patients with DGF or those 
with a rising serum creatinine are patients who would ordi-
narily undergo a biopsy to establish the etiology of their renal 
dysfunction. In the 14 patients with DGF, five (36%) had bor-
derline changes, three (21 %) had Banff 1 A-2A tubulitis, and 
six (43%) had no tubulitis on the one-week biopsies. In the 
46 patients with a rising serum creatinine at the time of the 
one-week biopsy, 14 (30%) had borderline changes, 13 
(28%) had Banff 1 A-2A tubulitis, and 19 (41 %) had no tu-
bulitis on the one-week biopsy. 
Discussion 
This report represents an initial analysis of our early experi-
ence with protocol biopsies. We confined the analysis to an 
ideal subgroup of patients, i.e. those without DGF, who had 
stable or improving renal function. These patients had no clin-
ical indication for renal allograft biopsy, yet over 40% of them 
had evidence of subclinical borderline or frank acute tubulitis, 
ranging from Banff 1 A to Banff 2A. We have previously de-
scribed the successful treatment of borderline histopathology 
with augmented immunosuppression, and have tended to 
think of it as a very mild form of rejection (17). The only ap-
parent difference between the patients with subclinical bor-
derline or acute tubulitis and those without rejection was a 
significantly lower (but still conventionally therapeutic) tacrol-
imus level on the day of the biopsy, in the patients with bor-
derline or acute tubulitis. 
This experience confirms the work of Rush et al. who have 
contended that there is a substantial incidence of subclinical 
acute tubulitis that ordinarily goes undetected (5-7). It sug-
gests that we may have been underestimating the true inci-
dence of acute rejection in our patients. 
The significance of the observation of a high incidence of 
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subclinical tubulitis is subject to varying interpretations. Cer-
tainly. one possible view is that these histopathologic 
changes, in the absence of any evidence of renal dysfunc-
tion, are of no consequence, and that treatment with aug-
mented immunosuppression is unnecessary, gratuitous, and 
perhaps harmful. Another view, and one that is consistent 
with the late protocol biopsy studies that have shown a high 
incidence of chronic allograft nephropathy (18), is that im-
munosuppression has become so powerful that rejection 
may not even be manifested by a rising serum creatinine. 
Unfortunately, undiagnosed, and therefore untreated subclin-
ical acute tubulitis may behave similarly to clinically apparent 
acute tubulitis and increase the risk for the development of 
chronic allograft nephropathy. Certainly, the randomized trial 
data from Winnipeg suggest that renal function and graft sur-
vival are better two years after transplantation in patients un-
dergoing more frequent biopsies, and therefore undergoing 
more frequent treatment for subclinical acute tubulitis (5-7). 
Most of the patients described in our series were already in 
a randomized trial of different immunosuppressive protocols, 
and it was not feasible to randomize them further on the 
basis of the results of the protocol biopsies. 
The potential benefits of discovering unsuspected acute tu-
bulitis have to be balanced against the risks associated with re-
nal allograft biopsies. Our incidence (0.4%) of major hemor-
rhagic complications was reasonably low, but emphasizes that 
there is some risk associated with renal allograft biopsies. We 
have not noted an increased incidence of opportunistic infec-
tions, although this is also a potential concem. 
In conclusion, we observed, in an analysis of one-week biop-
sies in 28 patients who had ideal clinical courses and stable 
renal function after transplantation, a 21 % incidence of sub-
clinical borderline changes and a 25% incidence of subclin-
ical acute tubulitis. This observation suggests that it is poss-
ible that the true incidence of acute rejection may be higher 
than we have clinically appreciated. 
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